ClinicalTrials.gg
Not yet recruitingNCT07131826Updated Aug 20, 2025

The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine

An observational study in Viral Control, Quality of Life and Cabotegravir, sponsored by National Taiwan University Clinical Trial Center. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by National Taiwan University Clinical Trial Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · Taiwan.

Started
2025
the only one that year
Observational
10 of 22
2 open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
National Taiwan University Clinical Trial Center

Among the 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan, this one is the only one that started in 2025, is one of 10 observational ones, and was the 21st registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

3 of the 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

"AIDS" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.

03

Conditions studied

  • Viral Control
  • Quality of Life
  • Cabotegravir
  • Rilpivirine
  • AIDS

Keywords

  • cabotegravir
  • rilpivirine
  • AIDS
  • quality of life
  • viral control
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males or females aged 18 years or older who have completed long-acting injectable treatment for HIV infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

18 years and above Clinical diagnosis of infection completed long-acting injectable treatment Accept the questionnaire

Exclusion criteria

Exclusion Criteria:

Not clinical diagnosis of infection Do not accept questionnaires

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • AIDS patients after long-acting injection of cabotegravir and rilpivirine

    AIDS patients after long-acting injection of cabotegravir and rilpivirine

    Other: Observational study, non-interventional

Interventions

  • OtherObservational study, non-interventional

    Observational study, non-interventional

06

What researchers measure

Primary outcomes

  1. To whether long-acting injections can significantly improve the quality of daily life of people infected with HIV using a questionnaire

    Time frame: From the date of approval by the CTC to December 31, 2026.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Does the long-acting injection improve the quality of daily life of HIV-infected people?

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

Of 165 non-industry observational studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 16 months is below that.

Counting every sponsor, half of 177 studies reached it within 44 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
Aug 20, 2025
StartEst.
Aug 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07131826
Lead sponsor
National Taiwan University Clinical Trial Center
Responsible party
National Taiwan University Clinical Trial Center (WANG-HUEI SHENG professor, National Taiwan University Hospital) — Sponsor-investigator
First posted
Aug 20, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 20, 2025

Study contacts

WANG-HUEI SHENG
Contact
ntuhrec@ntuh.gov.tw
+886-02-2312-3456

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion